Back to results
US 11,229,662 B2Granted
Compositions and methods for the treatment of aberrant angiogenesis
AssigneeThe Schepens Eye Research Institute, Inc.
InventorsJoseph F. Arboleda-Velasquez, Leo A. Kim, Patricia A. D'Amore
Life of this patent
Estimating the term…
Abstract
The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.
Claims15
A method for inhibiting, treating, or preventing aberrant angiogenesis or small vessel diseases (SVDs) in a subject, comprising:
- administering to said subject an effective amount of a Runt-Related Transcription Factor 1 (RUNX1) inhibitor,
- wherein the subject has proliferative diabetic retinopathy (PDR), macular edema, non-proliferative diabetic retinopathy, age-related macular degeneration (AMD), ocular neovascularization, ocular ischemic syndrome, retinopathy of prematurity (ROP), a retinal vein occlusion, ocular ischemic syndrome, neovascular glaucoma, a retinal hemangioma, Coates' disease, familial exudative vitreoretinopathy (FEVR), type 1 diabetes, type 2 diabetes, diabetic retinopathy (DR), a hemangioma, neovascular glaucoma, a vascular malformation, a cerebral cavernous malformation, Von Hippel-Lindau disease, Norrie disease, a melanoma, a solid tumor, or a cancer other than leukemia;
- and
- wherein said RUNX1 inhibitor binds to RUNX1 and/or CBFβ.
1 more element
Dependencies are inferred from the claim text.